Diffuse Large B-cell Lymphoma
📧 Sign up to get email alerts when something new happens for Diffuse Large B-cell Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2025-02-03Clinical Trial Update: Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphoma [Phase 1]
A Phase 1 clinical study evaluating duvortuxizumab plus ibrutinib in lymphomas has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2025-01-30Clinical Trial Update: A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) [Phase 2]
This Phase 2 trial evaluating Loncastuximab Tesirine in combination with Rituximab (Lonca-R) for previously untreated unfit/frail patients w…
-
CLINICAL_TRIALS trial_result · 2025-01-29Clinical Trial Update: Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma [Phase 1]
A Phase 1 trial evaluating the combination of chemotherapy with TAK-659 as front-line treatment for high-risk diffuse large B-cell lymphoma,…
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: An Italian Multicenter Retrospective Observational Study to Assess the Clinical Characteristics and the Outcome of Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin Plus Rituximab (± Bendamustine) Under Named Patient Programme
An Italian multicenter retrospective observational study evaluating the clinical characteristics and outcomes of relapsed or refractory diff…
-
CLINICAL_TRIALS trial_result · 2025-01-28Clinical Trial Update: Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma [Phase 2]
Phase 2 study evaluating anakinra to reduce CAR-T–related toxicity in patients with relapsed or refractory diffuse large B-cell lymphoma has…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-01-28Clinical Trial Update: Immunotherapy in Lymphoma
An ongoing immunotherapy trial for relapsed or refractory B-cell lymphomas is currently recruiting. The study targets high-grade B-cell lymp…
-
CLINICAL_TRIALS safety_alert · 2025-01-24Clinical Trial Update: A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma [Phase 2]
An update on a Phase 2 study evaluating adverse events of subcutaneous epcoritamab in adults with relapsed or refractory diffuse large B-cel…
-
CLINICAL_TRIALS research · 2025-01-24Clinical Trial Update: Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 3]
Phase 3 clinical trial assessing BEBT-908 plus Rituximab-based standard of care versus standard of care in relapsed/refractory diffuse large…
-
CLINICAL_TRIALS trial_result · 2025-01-23Clinical Trial Update: Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ [Phase 3]
Phase 3 trial evaluating enzastaurin added to R-CHOP in subjects with Diffuse Large B-Cell Lymphoma and the DGM1 genomic biomarker has compl…
-
CLINICAL_TRIALS research · 2025-01-23Clinical Trial Update: A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) [Phase 3]
A Phase 3 clinical trial update evaluating change in disease activity when subcutaneous epcoritamab is added to R-CHOP versus R-CHOP alone i…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study [EARLY_Phase 1]
An early-phase study evaluating whether exposing T cells to the PI3K inhibitor duvelisib can enhance immune profiles in patients with recurr…
-
CLINICAL_TRIALS research · 2025-01-20Clinical Trial Update: An Italian Multicentric Retrospective Observational Study to Assess Effectiveness and Safety of the Combination of Tafasitamab and Lenalidomide in Diffuse Large B-cell Lymphoma Patients Treated Under Named Patient Program
This clinical trial update notes an Italian multicenter retrospective observational study evaluating the effectiveness and safety of combini…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy
A completed clinical trial investigated the role of large extracellular vesicles as biomarkers in various lymphomas and lymphoproliferative …
-
CLINICAL_TRIALS trial_result · 2025-01-17Clinical Trial Update: A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL [Phase 1]
Phase 1 study evaluating glofitamab in combination with either rituximab or obinutuzumab plus CHOP, or polatuzumab vedotin plus rituximab wi…
-
CLINICAL_TRIALS trial_result · 2025-01-16Clinical Trial Update: AZA Combined with R-GemOx for Elderly DLBCL Patients [Phase 2]
This Phase 2 trial evaluates azacitidine plus rituximab-gemcitabine-oxaliplatin (R-GemOx) in elderly patients with diffuse large B-cell lymp…
-
CLINICAL_TRIALS trial_result · 2025-01-15Clinical Trial Update: Comparison of Whole-body MRI, Circulating DNA and PET-CT in Staging, Prognosis, and Treatment Response in Patients with Diffuse Large Cell B Lymphoma
A completed clinical trial evaluating whole-body MRI, circulating DNA, and PET-CT for staging, prognosis, and treatment response in patients…
-
CLINICAL_TRIALS trial_result · 2025-01-14Clinical Trial Update: Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma [Phase 2]
A Phase 2 clinical trial update indicates Sepantronium bromide is being studied for high-grade B-cell lymphomas, with the study currently ac…
-
CLINICAL_TRIALS research · 2025-01-14Clinical Trial Update: Role of Spectral CT in the Evaluation of Cardiotoxicity in Patients With Hodgkin's Lymphoma and Diffuse Large B-cell Lymphoma Treated With Anthracyclines
This clinical trial investigates the role of spectral CT in evaluating cardiotoxicity from anthracycline therapy in patients with Hodgkin ly…
-
CLINICAL_TRIALS research · 2025-01-13Clinical Trial Update: Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia [Phase 2]
Phase 2 clinical trial update on locally manufactured CAR T-cell products for multiple B-cell malignancies, including B-cell lymphoma and B-…
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients with CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine [Phase 3]
A Phase 3 trial evaluating rituximab-optimized therapy with liposomal vincristine for elderly patients with CD20+ diffuse large B-cell lymph…
-
CLINICAL_TRIALS trial_result · 2025-01-08Clinical Trial Update: Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas [Phase 2]
A Phase 2 study evaluating the triple combination therapy DTRM-555 in relapsed/refractory chronic lymphocytic leukemia and relapsed/refracto…
-
CLINICAL_TRIALS research · 2025-01-07Clinical Trial Update: Pixantrone as Bridging Therapy to Allogenic Transplant or CAR-T Cell Therapy in DLBCL Patients
Clinical trial update indicates pixantrone as bridging therapy to allogeneic transplant or CAR-T cell therapy in patients with diffuse large…
-
CLINICAL_TRIALS research · 2025-01-01Clinical Trial Update: PET Imaging Targeting Granzyme B Predicts Immunotherapy Efficacy in Diffuse Large B-cell Lymphoma
A clinical trial exploring Granzyme B–targeted PET imaging to predict immunotherapy efficacy in diffuse large B-cell lymphoma, currently rec…
-
CLINICAL_TRIALS research · 2024-12-30Clinical Trial Update: CR-CHOP+X in Previously Untreated DEL [Phase 2]
Phase 2 trial investigating CR-CHOP+X in patients with previously untreated diffuse large B-cell lymphoma (DEL), currently RECRUITING.
-
CLINICAL_TRIALS research · 2024-12-27Clinical Trial Update: CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) [Phase 2]
A Phase 2 clinical trial update evaluating the CD-RCHOP regimen in newly diagnosed diffuse large B-cell lymphoma with TP53 mutation and 17p …